Literature DB >> 12817034

Short term administration of costimulatory blockade and cyclophosphamide induces remission of systemic lupus erythematosus nephritis in NZB/W F1 mice by a mechanism downstream of renal immune complex deposition.

Lena Schiffer1, Jayashree Sinha, Xiaobo Wang, Weiqing Huang, Gero von Gersdorff, Mario Schiffer, Michael P Madaio, Anne Davidson, Gero Von Gonsdorff.   

Abstract

NZB/W F(1) mice with established nephritis were treated with a single dose of cyclophosphamide with or without a 2-wk course of murine CTLA4Ig, either alone or in combination with anti-CD154. Sixty to 80% of treated mice entered remission, and remission could be reinduced following relapse. A decrease in the frequency of anti-DNA-producing B cells and activated T cells was observed in treated mice, but this effect lasted only 3-6 wk, while remissions were sustained for up to 20 wk. Light microscopy of the kidneys of mice in remission revealed less glomerular inflammation, less tubular damage, and less infiltration of inflammatory cells. By immunofluorescence, however, IgG and C3 staining of glomeruli was no different in treated mice vs controls. Since chemokines and their receptors play an important role in inflammatory cell infiltration of affected organs in autoimmune diseases, we examined chemokine expression in the kidneys. Decreases in the expression of inflammatory cytokines and chemokines were evident in mice in the early stages of remission, but these differences were no longer present in late remission. Increased expression of CXCL13 was detected in the inflammatory infiltrates of the control NZB/NZW mice. Strikingly, we could not detect any CXCL13 in the kidneys of the treated group even in late remission. These findings suggest that costimulatory blockade together with cyclophosphamide influence the activation state of renal CD11c-positive cells and therefore lead to less B and T cell infiltration and nephritis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12817034     DOI: 10.4049/jimmunol.171.1.489

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  63 in total

1.  Cross-species transcriptional network analysis defines shared inflammatory responses in murine and human lupus nephritis.

Authors:  Celine C Berthier; Ramalingam Bethunaickan; Tania Gonzalez-Rivera; Viji Nair; Meera Ramanujam; Weijia Zhang; Erwin P Bottinger; Stephan Segerer; Maja Lindenmeyer; Clemens D Cohen; Anne Davidson; Matthias Kretzler
Journal:  J Immunol       Date:  2012-06-20       Impact factor: 5.422

2.  The histone peptide H4 71-94 alone is more effective than a cocktail of peptide epitopes in controlling lupus: immunoregulatory mechanisms.

Authors:  Hee-Kap Kang; Ming-Yi Chiang; Michael Liu; Diane Ecklund; Syamal K Datta
Journal:  J Clin Immunol       Date:  2011-02-03       Impact factor: 8.317

3.  Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis.

Authors:  Lena Schiffer; Ramalingam Bethunaickan; Meera Ramanujam; Weiqing Huang; Mario Schiffer; Haiou Tao; Michael P Madaio; Michael M Madaio; Erwin P Bottinger; Anne Davidson
Journal:  J Immunol       Date:  2008-02-01       Impact factor: 5.422

Review 4.  Dendritic cells and macrophages in the kidney: a spectrum of good and evil.

Authors:  Natasha M Rogers; David A Ferenbach; Jeffrey S Isenberg; Angus W Thomson; Jeremy Hughes
Journal:  Nat Rev Nephrol       Date:  2014-09-30       Impact factor: 28.314

5.  Identification of stage-specific genes associated with lupus nephritis and response to remission induction in (NZB × NZW)F1 and NZM2410 mice.

Authors:  Ramalingam Bethunaickan; Celine C Berthier; Weijia Zhang; Ridvan Eksi; Hong-Dong Li; Yuanfang Guan; Matthias Kretzler; Anne Davidson
Journal:  Arthritis Rheumatol       Date:  2014-08       Impact factor: 10.995

6.  Activated CD4+ T cells target mesangial antigens and initiate glomerulonephritis.

Authors:  Yogesh Scindia; Dominika Nackiewicz; Paromita Dey; Agnieszka Szymula; Amandeep Bajwa; Diane L Rosin; W Kline Bolton; Mark D Okusa; Umesh Deshmukh; Harini Bagavant
Journal:  Nephron Exp Nephrol       Date:  2012-10-19

Review 7.  Drugs in early clinical development for Systemic Lupus Erythematosus.

Authors:  Mariana Postal; Nailú Angélica Sinicato; Simone Appenzeller; Timothy B Niewold
Journal:  Expert Opin Investig Drugs       Date:  2016-04-07       Impact factor: 6.206

8.  ICOS controls effector function but not trafficking receptor expression of kidney-infiltrating effector T cells in murine lupus.

Authors:  Jared M Odegard; Leah D DiPlacido; Lark Greenwald; Michael Kashgarian; Dwight H Kono; Chen Dong; Richard A Flavell; Joe Craft
Journal:  J Immunol       Date:  2009-04-01       Impact factor: 5.422

9.  New and emerging treatment approaches to lupus.

Authors:  Marion Haubitz
Journal:  Biologics       Date:  2010-09-13

10.  Apigenin, a non-mutagenic dietary flavonoid, suppresses lupus by inhibiting autoantigen presentation for expansion of autoreactive Th1 and Th17 cells.

Authors:  Hee-Kap Kang; Diane Ecklund; Michael Liu; Syamal K Datta
Journal:  Arthritis Res Ther       Date:  2009-04-30       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.